| |
|
|
|
|
|
| |
Day 1 - 17 JUNE 2010 |
|
|
| |
|
|
|
|
|
| |
08:30 - 08:40 |
|
Welcome & Introduction |
EBF |
|
| |
|
|
|
|
|
| |
08:40 - 09:10 |
|
Plenary session |
Philip Timmerman (J&J, EBF) |
|
| |
|
|
|
|
|
| |
09:10 - 10:50 |
|
DBS in the non regulated environment Session |
| |
|
|
|
|
|
| |
09:10 - 09:30 |
|
keynote speaker |
K. Beaumont (Pfizer) |
Who decided we should measure plasma? |
| |
09:30 - 09:45 |
|
oral presentation 1 |
F. Picard (Novartis) |
"An overview of the implementation of Dried Blood Spots (DBS) at Novartis: results and next step" |
| |
09:45 - 10:00 |
|
oral presentation 2 |
P. Wright (Pfizer) |
Dried Blood Spots for Metabolite Identification: Can we ? Should we ? |
| |
10:15 - 11:30 |
|
oral presentation 3 |
C. Smith (AstraZeneca) |
Metabolite profiles from Dried Biofluid Spots for Metabonomic studies using UPLC combined with oaTOF-MS |
| |
10:30 - 10:50 |
|
panel discussion |
|
|
| |
|
|
|
|
|
| |
10:50 - 11:20 |
|
Break |
|
|
| |
|
|
|
|
|
| |
11:20 - 12:30 |
|
Combined Poster and tutorial |
|
| |
|
|
tutorials in breakout format |
tutorial 1 |
Sampling from small animals (moderator identified) |
| |
|
|
tutorial 2 |
Practical aspects of spotting on cards (moderator identified) |
| |
|
|
|
tutorial 3 |
Instrumental aspects of card punching (moderator identified) |
| |
|
|
|
tutorial 4 |
Sampling in the clinic or in phase 3 trials |
| |
|
|
|
tutorial 5 |
Logistics and regulatory aspects of shipping of cards |
| |
|
|
|
|
|
| |
|
|
|
|
|
| |
12:30 - 13:30 |
|
Lunch |
|
|
| |
|
|
|
|
|
| |
|
|
|
|
|
| |
13:30 - 15:30 |
|
Combined Tox/regulatory/QA Session |
|
| |
|
|
|
|
|
| |
|
|
TOX |
|
|
| |
13:30 - 13:50 |
|
keynote speaker |
F. McClure (GSK) |
Spot the Difference – effect of TK blood sampling on Clinical Pathology parameters |
| |
13:50 - 14:05 |
|
oral presentation 1 |
L. Patrone (BMS) |
Direct Comparison of Dried Blood Spot (DBS) Analysis to Plasma and Whole Blood Analysis in Toxicokinetic Studies of Rats |
| : |
14:05 - 14:20 |
|
oral presentation 2 |
Speaker to be identified |
|
| |
14:20 - 14:35 |
|
oral presentation 3 |
J. Burnett (Covance) |
Practical Application of Dried Blood Spot Techniques in Toxicology |
| |
|
|
|
|
|
| |
|
|
REG/QA |
|
|
| |
14:35 - 15:10 |
|
keynote speaker |
M. Benton (Fulcrum Pharma) |
QA perspective on Dried Blood Spot analysis |
| |
|
|
|
|
|
| |
15:10 - 15:30 |
|
panel discussion |
|
|
| |
|
|
|
|
|
| |
15:30 - 16:00 |
|
Break |
|
|
| |
|
|
|
|
|
| |
|
|
|
|
|
| |
16:00 -18:00 |
|
Bioanalytical and DBS: applications |
|
| |
|
|
|
|
|
| |
16:00 - 16:20 |
|
keynote speaker |
P. Abu-Rabie (GSK) |
Direct quantitative bioanalysis of drugs in dried blood spot samples |
| |
16:20 - 16:40 |
|
oral presentation 1 |
H. Ghobarah (AB Sciex) |
High Sensitivity LC/MS/MS Quantification of Corticosteroids in Dried Blood Spots and Evaluation of Software Saturation Correction for Extending Dynamic Range |
| |
16:40 - 17:00 |
|
oral presentation 2 |
M. Barfield (GSK) |
The use of Dried Plasma Spots (DPS) and Dried Urine Spots (DUS) for LC/MS/MS assays |
| |
17:00 - 17:20 |
|
oral presentation 3 |
A. Gajate Perez (Roche) |
Can Dried Blood Spot technique be used to stabilize ester pro-drugs and glucuronide metabolites? |
| |
17:20 - 17:40 |
|
oral presentation 4 |
L. Goodwin (Covance) |
Quantitative Determination of a Therapeutic Peptide in Dried Blood Spots |
| |
17:40 - 18:00 |
|
panel discussion |
|
|
| |
|
|
|
|
|
| |
18:00 - 19:00 |
|
Complementary cocktail reception |
|
| |
|
|
|
|
|
